Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma

Journal of Investigative Dermatology

Volumn 133, Issue 6, 2013, Pages 1582-1590

  Khoja, Leila ^a   Lorigan, Paul ^b,c   Zhou, Cong ^a   Lancashire, Matthew ^a   Booth, Jessica ^a   Cummings, Jeff ^a   Califano, Raffaele ^b   Clack, Glen ^d   Hughes, Andrew ^c,d   Dive, Caroline ^a,c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DACARBAZINE; LACTATE DEHYDROGENASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR;

ADULT; AGE; AGED; ARTICLE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CELL COUNT; CIRCULATING TUMOR CELL; COMPUTER ASSISTED TOMOGRAPHY; CUTANEOUS MELANOMA; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEX;

EID: 84878562438     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2012.468     Document Type: Article

References (25)

1. Altman DG, McShane LM, Sauerbrei W et al. (2012) Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. BMC Med 10:51
2. Campoli MR, Chang CC, Kageshita T et al. (2004) Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. Crit Rev Immunol 24:267-96
3. Chapman PB, Hauschild A, Robert C et al. (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-16
4. Cohen SJ, Punt CJ, Iannotti N et al. (2008) Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 26:3213-21
5. Cristofanilli M, Budd GT, Ellis MJ et al. (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351:781-91
6. Cummings J, Zhou C, Dive C (2011) Application of the beta-expectation tolerance interval to method validation of the M30 and M65 ELISA cell death biomarker assays. J Chromatogr B Analyt Technol Biomed Life Sci 879:887-93
7. Curtin JA, Busam K, Pinkel D et al. (2006) Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24:4340-6
8. Curtin JA, Fridlyand J, Kageshita T et al. (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med 353:2135-47
9. Davies H, Bignell GR, Cox C et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417:949-54
10. de Bono JS, Scher HI, Montgomery RB et al. (2008) Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14:6302-9
11. De Giorgi V, Pinzani P, Salvianti F et al. (2010) Application of a filtration- and isolation-by-size technique for the detection of circulating tumor cells in cutaneous melanoma. J Invest Dermatol 130:2440-7
12. Efron B, Tibshirani R (1993) An Introduction to the Bootstrap. Chapman & Hall: New York
13. Hodi FS, O'Day SJ, McDermott DF et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-23
14. Hou JM, Greystoke A, Lancashire L et al. (2009) Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy. Am J Pathol 175:808-16
15. Hou JM, Krebs MG, Lancashire L et al. (2012) Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol 30:525-32
16. Jiang Y, Palma JF, Agus DB et al. (2010) Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer. Clin Chem 56:1492-5
17. Kraan J, Sleijfer S, Strijbos MH et al. (2011) External quality assurance of circulating tumor cell enumeration using the CellSearch((R)) system: a feasibility study. Cytometry B Clin Cytom 80:112-8
18. Krebs MG, Sloane R, Priest L et al. (2011) Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol 29:1556-63
19. Long GV, Menzies AM, Nagrial AM et al. (2011) Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 29:1239-46
20. McShane LM, Altman DG, Sauerbrei W et al. (2005) REporting recommendations for tumour MARKer prognostic studies (REMARK). Eur J Cancer 41:1690-6
21. Nezos A, Lembessis P, Sourla A et al. (2009) Molecular markers detecting circulating melanoma cells by reverse transcription polymerase chain reaction: methodological pitfalls and clinical relevance. Clin Chem Lab Med 47:1-11
22. Rao C, Bui T, Connelly M et al. (2011) Circulating melanoma cells and survival in metastatic melanoma. Int J Oncol 38:755-60
23. Ribas A, Flaherty KT (2011) BRAF targeted therapy changes the treatment paradigm in melanoma. Nat Rev Clin Oncol 8:426-33
24. Shih IM (1999) The role of CD146 (Mel-CAM) in biology and pathology. J Pathol 189:4-11
25. Smith B, Selby P, Southgate J et al. (1991) Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 338:1227-9